Search clinical trials for: Pegylated Interferon Alfa 2a

Total 1101 results

Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C

Hepatitis C

Taiwan
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
BioGeneric Pharma
Xiamen Amoytop Biotech Co., Ltd.

Unknown

Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

Hepatitis C | Self Efficacy

Egypt
Hoffmann-La Roche

Terminated

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Hepatitis C, Chronic

Romania
University Hospital Tuebingen
Dermatologic Cooperative Oncology Group

Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Melanoma

Germany
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
José Antonio Carrion
Instituto de Salud Carlos III

Completed

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic Hepatitis B (HBeAg-negative)
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaborators

Completed

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

HIV Infections

United States
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (SAEI_IFN_1)

HIV Infections | Hepatitis C, Chronic

Spain
Hanyang University
Roche Pharma AG

Unknown

Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B. (POTENT)

Hepatitis B, Chronic

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Hepatitis D, Chronic

Romania
Bristol-Myers Squibb

Withdrawn

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Hepatitis C Virus (HCV)

India, Korea, Republic of, Poland, Taiwan, Spain, Canada, Russian Federation, Colombia, Singapore, Netherlands, Ireland, United Kingdom, Czech Republic, Hungary, Romania, Hong Kong, Turkey, United States, China, Egypt
Kaohsiung Medical University Chung-Ho Memorial...

Completed

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

Chronic Hepatitis C | Genotype

Taiwan
King Abdulaziz Medical City

Completed

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Chronic Hepatitis C Virus

Saudi Arabia
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
Beijing Ditan Hospital

Completed

HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated

Chronic Hepatitis B

China
Arbutus Biopharma Corporation

Active, not recruiting

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Chronic Hepatitis b

United States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
Yonsei University

Completed

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

Chronic Hepatitis B

Korea, Republic of
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
Johannes Gutenberg University Mainz
Roche Pharma AG

Completed

Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen (PADD-ON)

Chronic Hepatitis B

Germany
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
National Institute of Allergy and Infectious Diseases...

Completed

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients (PIFNPK)

HIV Infections | Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin

Hemodialysis | Chronic Hepatitis C

Taiwan
Amr Hafez
Ain Shams University

Completed

Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Hepatitis C
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Brain and Central Nervous System Tumors

United States
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Hepatitis B, Chronic

Italy
Chronic Liver Disease Foundation
Merck Sharp & Dohme LLC; SCRI Development Innovations, LLC

Completed

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (OPTIMAL)

Chronic Hepatitis C | Genotype 1

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Hepatitis C

United States, Canada, Netherlands, Puerto Rico, Germany
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
M.D. Anderson Cancer Center

Withdrawn

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C

United States
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
Göteborg University
Hoffmann-La Roche

Terminated

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin (RelapC)

Chronic Hepatitis C

Sweden

3

Subscribe